1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Acute Pancreatitis (AP) – Market Insights, Epidemiology, and Market Forecast—2030

Acute Pancreatitis (AP) – Market Insights, Epidemiology, and Market Forecast—2030

  • January 2021
  • 132 pages
  • ID: 6025262
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Acute Pancreatitis (AP) – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Acute Pancreatitis (AP), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Acute Pancreatitis (AP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted AP symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Acute Pancreatitis (AP) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Acute Pancreatitis (AP) Disease Understanding and Treatment Algorithm

Acute Pancreatitis (AP) Overview
Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas that presents as severe upper abdominal pain, often accompanied by nausea and vomiting. In acute pancreatitis, which has numerous causes, inflammation of the pancreas occurs, which can lead to pancreatic cell death or necrosis and systemic inflammation, a precursor to organ failure. Normal pancreatic functions, such as the secretion of digestive enzymes required to break down food in the gut, are disabled.
It may range in severity from self-limiting, characterized by mild pancreatic edema, to severe systemic inflammation with pancreatic necrosis, organ failure and death. There are several clinical, laboratory, and radiologic risk factors and scoring systems that are used to predict severity of AP, but none is optimal. Severe complications arise due to the acute inflammatory response that takes place in the pancreas. These complications can lead to systemic inflammatory response syndrome, or SIRS, in which the function of other tissues including the lung are compromised. Approximately one third of patients with severe acute pancreatitis develop acute lung injury or ARDS. Lung failure accounts for 60% of deaths associated with acute pancreatitis in developed countries.
Acute pancreatitis usually begins with gradual or sudden pain in the upper abdomen that sometimes extends to the back. The pain may be mild at first and become worse after eating. The pain is often severe, constant, and commonly lasts for several days in the absence of treatment. A person with acute pancreatitis usually looks and feels very ill and needs immediate medical attention. Most cases require hospitalization for 3 to 5 days for close monitoring, pain control, and intravenous hydration. Other symptoms can include: swollen and tender abdomen, nausea and vomiting, fever and rapid pulse.
The diagnosis of acute pancreatitis requires at least 2 of the following: typical upper abdominal pain, elevated levels of amylase or lipase, and confirmatory findings from cross-sectional imaging analysis. Although, the disease is usually confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for the pancreas’ digestive enzymes. Blood amylase or lipase levels are typically elevated 3 times the normal level during acute pancreatitis. In some cases, when the blood tests are not elevated, and the diagnosis is still in question, abdominal imaging, such as a computed tomography (CT) scan, might be performed.

Acute Pancreatitis (AP) Diagnosis and Treatment
It covers the details of conventional and current medical therapies, and diagnosis available in the Acute Pancreatitis (AP) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Acute Pancreatitis (AP) market report gives a thorough understanding of AP symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides AP symptoms of treatment algorithms and treatment guidelines for AP symptoms in the US, Europe, and Japan.

Acute Pancreatitis (AP) Epidemiology
The epidemiology division’s Acute Pancreatitis symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Acute Pancreatitis (AP) epidemiology segmented as the Diagnosed Incident Cases of Acute Pancreatitis (AP), Gender-specific cases of Acute Pancreatitis (AP), Diagnosed Incident Cases of Acute Pancreatitis (AP) by Etiology and Diagnosed Incident Cases of Acute Pancreatitis (AP) by Severity. The report includes the Incident scenario of AP symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Acute Pancreatitis (AP) Epidemiology
The epidemiology segment also provides the Acute Pancreatitis (AP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM incident cases of Acute Pancreatitis (AP) were 502,390 in 2020.

Acute Pancreatitis (AP) Drug Chapters
The drug chapter segment of the Acute Pancreatitis (AP) report encloses the detailed analysis of AP drugs. It also helps understand the Acute Pancreatitis (AP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Acute Pancreatitis (AP) Emerging Drugs
CalciMedica’s lead product candidate, Auxora (formerly CM4620), a proprietary intravenous-formulated CRAC channel inhibitor, is being developed for several indications including the treatment of acute inflammatory diseases associated with dysregulation of intracellular calcium in organ tissues like the lung, pancreas or kidneys such as that of Acute Pancreatitis (AP).
Products detail in the report…

Acute Pancreatitis (AP) Market Outlook
The Acute Pancreatitis (AP) market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Acute Pancreatitis (AP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Acute Pancreatitis (AP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, Acute Pancreatitis (AP) market in 7MM is expected to change in the study period 2017–2030.

Key Findings
This section includes a glimpse of the Acute Pancreatitis (AP) market in 7MM. The market size of AP in the seven major markets was found to be USD 710.61 million in 2020 and market is estimated to increase at a CAGR of 5.89% for the study period (2017–2030).

The United States Market Outlook
This section provides a total of Acute Pancreatitis (AP) market size and market size by therapies in the United States.
The United States accounts for the highest AP market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Acute pancreatitis is one of the most frequent gastrointestinal cause of hospital admissions in the US where patients typically present with severe, continuous upper abdominal pain radiating to the back. There are several factors which have led to an increase in the incidence of AP such as increasing incidence of obesity which promotes gallstone formation along with the increased availability of and use of tests to measure serum levels of pancreatic enzymes, which detect milder cases of AP.

EU-5 Countries: Market Outlook
The total Acute Pancreatitis (AP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Acute Pancreatitis (AP) market size and market size by therapies in Japan are mentioned in this section.

Acute Pancreatitis (AP) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Acute Pancreatitis (AP) market uptake by drugs; patient uptake by therapies; and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Acute Pancreatitis (AP) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute Pancreatitis (AP) key players involved in developing targeted therapeutics.
Major players include Auxora (CalciMedica) being assessed as potential therapies to be available in the market in the coming future.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Acute Pancreatitis (AP) emerging therapies.
Reimbursement Scenario in Acute Pancreatitis (AP)
While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to make sure that the patient receives Social Security Disability benefits as quickly as possible and will help the patient avoid the lengthy disability appeal process
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Acute Pancreatitis (AP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Acute Pancreatitis (AP) market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Acute Pancreatitis (AP) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Acute Pancreatitis (AP), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Acute Pancreatitis (AP) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Pancreatitis (AP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Acute Pancreatitis (AP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Pancreatitis (AP) market

Report Highlights
• In the coming years, Acute Pancreatitis (AP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pancreatitis (AP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for AP. The launch of emerging therapies will significantly impact the Acute Pancreatitis (AP) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for AP.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acute Pancreatitis (AP) Report Insights
• Patient Population
• Therapeutic Approaches
• Acute Pancreatitis (AP) Pipeline Analysis
• Acute Pancreatitis (AP) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Acute Pancreatitis (AP) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Acute Pancreatitis (AP) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Acute Pancreatitis (AP) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Acute Pancreatitis (AP) Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Acute Pancreatitis (AP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the market’s key findings across 7MM and which country will have the largest Acute Pancreatitis (AP) market Size during the forecast period (2017–2030)?
• At what CAGR, the Acute Pancreatitis (AP) market is expected to grow by 7MM during the forecast period (2017–2030)?
• What would be the Acute Pancreatitis (AP) market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Acute Pancreatitis (AP) market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of the Acute Pancreatitis (AP)?
• What is the historical Acute Pancreatitis (AP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
• What would be the forecasted patient pool of Acute Pancreatitis (AP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Acute Pancreatitis (AP)?
• Out of all 7MM countries, which country would have the highest incident population of Acute Pancreatitis (AP) during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow by 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Acute Pancreatitis (AP)?
• What are the current treatment guidelines for treating Acute Pancreatitis (AP) in the USA, Europe, and Japan?
• What are the Acute Pancreatitis (AP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Acute Pancreatitis (AP)?
• How many therapies are developed by each company for the treatment of Acute Pancreatitis (AP)?
• How many emerging therapies are in the mid-stage and late stages of development to treat Acute Pancreatitis (AP)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Pancreatitis (AP) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Pancreatitis (AP) and their status?
• What are the key designations that have been granted for the emerging therapies for Acute Pancreatitis (AP)?
• What are the global historical and forecasted market of Acute Pancreatitis (AP)?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Acute Pancreatitis (AP) market
• To understand the future market competition in the Acute Pancreatitis (AP) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Acute Pancreatitis (AP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Acute Pancreatitis (AP) market
• To understand the future market competition in the Acute Pancreatitis (AP) market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

2021 Disposable Blood Pressure Cuffs Market - Size, Share, COVID Impact Analysis and Forecast to 2027

  • $ 4580
  • March 2021
  • 102 pages

2021 Disposable Blood Pressure Cuffs Market - Size, Share, COVID Impact Analysis and Forecast to 2027 Global Disposable Blood Pressure Cuffs Market is valued at USD 197.8 million in 2020 and is expected ...

  • United States
  • World
  • Respiratory Disease
  • Medical Waste Management
  • Industry analysis
  • Health Expenditure
  • Cancer Incidence

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on